Notice of Revised NIH Definition of “Clinical Trial”
Release Date: October 23, 2014
National Institutes of Health (NIH)
The purpose of this Notice is to inform the research community that NIH has revised its definition of “clinical trial.” The revision is designed to make the distinction between clinical trials and... FULL STORY
On Oct. 17, the Lexington Convention Center teemed with more than 200 students and scientists sharing their latest research on cardiovascular health for the 17th annual Gill Heart Institute Cardiovascular Research Day.
Nigel Mackman, Ph.D., director of the McAllister Heart Institute at the University of North Carolina at Chapel Hill, presented "Hematosis, Thrombosis and Immunity," demonstrating the... FULL STORY
The Sanders-Brown Center on Aging at the University of Kentucky will hold its fourth annual Markesbery Symposium on Aging and Dementia on Friday and Saturday, Nov. 21-22.
The Markesbery Symposium is named in honor of the late Dr. William R. Markesbery, founder and long-time director of the UK Sanders-Brown Center on Aging and an internationally renowned expert on aging and dementia.
More than 5 million Americans have Alzheimer's disease (AD) today and millions more are affected by their role as family member, friend or caregiver to those with memory loss. The Markesbery Symposium was established to improve awareness of and education about AD and the latest... FULL STORY
Two independent groups of researchers led by Sidney "Wally" Whiteheart, PhD, at the University of Kentucky, and Dr. Charles Lowenstein, at the University of Rochester, have published important studies exploring the role that a gene called STXBP5 plays in the development of cardiovascular disease.
According to Whiteheart, previous genome-wide association studies (GWAS) identified a gene called STXBP5 as a factor that regulates a protein called Von Willebrand factor (VWF).
VWF is an important contributor to normal blood clotting. When the endothelial cells that line a blood vessel are injured, VWF is released into the bloodstream, where it "collects" blood... FULL STORY
A new study by University of Kentucky researchers has identified a novel molecule named Arylquin 1 as a potent inducer of Par-4 secretion from normal cells. Par-4 is a protein that acts as a tumor suppressor, killing cancer cells while leaving normal cells unharmed.
Normal cells secrete small amounts of Par-4 on their own, but this amount is not enough to kill cancer cells. Notably, if Par-4 secretion is suppressed, this leads to tumor growth.
Published in "Nature Chemical Biology," the UK study utilized lab cultures and animal models to show that low levels of Arylquin 1 induced Par-4 secretion without causing harm to the producer cells.
Additionally,... FULL STORY
Did you know that you can help others by participating in research? Health-focused research affects every aspect of our lives, from the medications we take to the health of our environment. Researchers are working hard to identify new treatments and strategies to improve the health of our communities, but research needs healthy volunteers and volunteers with medical conditions in order to succeed. Participating in research is a safe, easy way for you to give back to your community and give hope for the future while learning more about your own health.
Find out how you can participate in research during the University of Kentucky's next #AskACat Twitter chat,... FULL STORY
A team of investigators has made a thought-provoking discovery about a type of cholesterol previously believed to be a "bad guy" in the development of heart disease and other conditions.
Jason Meyer, a University of Kentucky M.D.-Ph.D. candidate, worked with Deneys van der Westhuyzen, a professor in the departments of Internal Medicine and Molecular and Cellular Biochemistry, to study the role oxidized LDL plays in the development of plaque inside artery walls.
According to Meyer, the medical research community has traditionally believed that oxidized LDL plays a pivotal role in that process.
"Oxidized LDL moves rapidly into arterial walls and engorges them... FULL STORY
Studies show that adults who received corrective surgery for the most common serious form of congenital heart disease as infants are susceptible to heart failure in adulthood.
Researchers at the University of Kentucky are using magnetic resonance imaging (MRI) technology to better understand the cause of heart failure in these patients, with the goal of eventually developing new therapies to reduce mortality. The team, led by University of Kentucky professor Dr. Brandon Fornwalt, recently published their findings in an article appearing in the European Heart Journal titled, "Patients with Repaired Tetralogy of Fallot Suffer From Intra- and Inter-Ventricular Cardiac... FULL STORY
University of Kentucky associate professor Dr. Matthew Gentry, a biochemist who studies the very basic makeup of living things, can count very few "Eureka!" moments in his scientific career.
One of those moments occurred while he was studying the genetic mutation associated with Lafora's disease, a type of epilepsy that inevitably causes death from neurodegeneration early in life. He was conducting post-doctoral research at University of California-San Diego to determine what happens within the cells of children born with Lafora's disease. He was examining the role of the protein laforin, the mutation that causes the disease. He and a colleague performed a series of... FULL STORY
Tetsuhiro Yasuma, postdoctoral Fellow in the Department of Ophthalmology and Visual Sciences at the University of Kentucky College of Medicine, has been selected to receive the 2014 Fight for Sight Postdoctoral Award from Fight for Sight, a non-profit organization that promotes eye research by providing pilot funding to promising new researchers.
Yasuma received training in biomedical research as an undergraduate student in Japan and general ophthalmology and surgery in graduate school. Yasuma joined the Ambati lab at UK in 2012. His research focuses on finding treatment for dry Age-Related Macular Degeneration (AMD), the form of AMD that affects the majority of AMD... FULL STORY
Dr. Peter T. Nelson of the Sanders-Brown Center on Aging (SBCoA) at the University of Kentucky, and David Fardo of UK's Department of Biostatistics, have been awarded the 2014 Asao Hirano Prize from the American Association of Neuropathologists (AANP) for the best paper presented on neurodegenerative diseases at its annual meeting in Portland, Oregon, last month.
The team's research, titled "Hippocampal Sclerosis of Aging (HS-A): Connecting Genomics and Other Risk Factor Data," compared 363 persons with autopsy-proven HS-A to a control group of 2,303 other individuals in an attempt to identify genetic predisposition to HS-A in what's called a genome-wide association... FULL STORY
A new study by University of Kentucky researchers shows how a genetic defect in a specific hormonal pathway may make people more susceptible to developing melanoma, the deadliest type of skin cancer.
Fair-skinned people who tend to burn (rather than tan) from sun exposure have a much higher risk for melanoma than darker-skinned people. On the surface, it appears that the amount of melanin, the natural substance in the skin that determines pigment and acts as the skin's "natural sunscreen," would be the only determinant of melanoma risk. However, the truth is more complicated.
Published in Molecular Cell, the study looked at the role of the melanocortin1 receptor... FULL STORY
The Bright Focus Foundation has announced that three different researchers from the Sanders-Brown Center on Aging at the University of Kentucky have received Bright Focus grants for 2014.
Professor Steve Estus and associate professors Harry LeVine and Paul Murphy were each recognized for their work on Alzheimer's disease.
"Only 25 Bright Focus grants are awarded worldwide each year, so it's an achievement to get one. But three Bright Focus grants in a single year is truly exceptional," said Dr. Michael Karpf, UK HealthCare's executive vice president of health affairs. "These awards are an appropriate reflection of Sanders-Brown's international reputation for... FULL STORY
Researchers from the Sanders-Brown Center on Aging at the University of Kentucky have been able to confirm anecdotal information on patients with both Alzheimer's disease (AD) and cerebrovascular disease (CVD) using mouse models in two different studies.
The findings of these two studies, which were recently published in Acta Neuropathologica and Alzheimer's Research... FULL STORY